Skip to main content
OpenTrials
Completed

NCT Number: NCT07307131

Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts

This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cutaneous Warts Human Papilloma Virus (HPV)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

faculty of Medicine

Banhā, Qalyubia Governorate, 13518, Egypt

About this study

This is a prospective, randomized, single-blind, comparative clinical study to evaluate the efficacy and safety of intralesional combined furosemide-digoxin versus intralesional polidocanol in the treatment of cutaneous warts. Sixty-four adult patients were randomized to receive one of the two treatments every two weeks for a maximum of four sessions. The main goal was to see which treatment was better at completely clearing the warts. The study also looked at side effects and how often the warts came back within six months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients over 18 years of age with single or multiple cutaneous warts.

Exclusion criteria

  • History of allergies to the study medications, known cardiac or renal disease, hypertension, pregnancy or lactation, and any signs of systemic or local infection.

Treatment and study plan

Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

Drug

Group A (Experimental): Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

Intralesional polidocanol 2%

Drug

Group B (Active Comparator): Intralesional polidocanol 2%

Primary outcomes

  1. Complete Clinical Response

    Time frame: Up to 8 weeks

    100% clearance of the treated wart at the end of the treatment period.

Secondary outcomes

  1. Incidence and Severity of Adverse Effects

    Time frame: Throughout the treatment period (up to 8 weeks)

    Assessment of side effects such as pain, erythema, edema, and ulceration.

  2. Recurrence Rate

    Time frame: 6 months post-treatment

    Rate of wart recurrence at the 6-month follow-up visit

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Official study title

A Head-to-Head Comparison of Intralesional Furosemide-Digoxin Versus Polidocanol for the Treatment of Cutaneous Warts With 6-Month Follow-up

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Dec 29, 2025
Registry last updated
Jan 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.